NR3C1 and non-small cell lung carcinoma: Specifically, whether the GR affects the expression of immune checkpoint inhibitors in NSCLC should be evaluated, since there is already evidence that GR signaling regulates PD-L1 expression and, thus, promotes immune evasion and immunotherapy resistance in other cancers [37,38,39].